IM011-1128 Enrolling

Teen Plaque Psoriasis Research Trial (78 Weeks)


Treatment: Oral Age: 12 Years


Who Can Participate?

Adolescents 12 to <18 years of age with plaque psoriasis, may be eligible.

 

Inclusion Criteria:

      • Diagnosis of stable plaque psoriasis for 6 months or more
      • Moderate to severe psoriasis, including a Body Surface Area (BSA) ≥ 10% involvement
      • Permitted to enroll with a medical history or symptoms suggestive of Juvenile Psoriatic Arthritis (JPsA) as long as treatment of JPsA does not require prohibited medications
      • Have all immunizations up-to-date

 

Participant Info:

      • No cost to participate or receive study medication
      • Regular visits with study doctors who are familiar with treating plaque psoriasis
      • Will receive investigational oral medication (active study drug) or placebo, during the main study
      • Reimbursement for study-related expenses may be provided

 

How Long Will The Study Last?

      • In the main study, individuals will be asked to visit the study centre about 14 times over a period of about 78 weeks.  The main study will be followed by an optional open-label long-term extension (LTE) period with a duration of up to 5 years.

Participating Locations

COUNTRY
country-icon
United States
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: September 09, 2025

Official Title

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis

ClinicalTrials.gov ID

NCT06979453

Sponsor

Bristol-Myers Squibb

Study Description

  • Brief Summary:

    The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis.

  • Condition or Disease:

    Plaque Psoriasis

  • Intervention/Treatment:

    Drug: Deucravacitinib Other: Placebo
  • Phase:

    PHASE 3

  • Ages Eligible for Study:

    12 Years and 17 Years (CHILD)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Psoriasis - Adolescent

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content